Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Despite its great promise, neuroimaging has yet to substantially impact clinical practice and
public health. However, a developing synergy between emerging analysis techniques and …

In the long-term, with progression of the illness, Parkinson's disease dementia affects up to
90% of patients with Parkinson's disease. With increasing life expectancy in western …

Parkinson's disease is a chronic progressive neurodegenerative disorder characterized by
resting tremor, slowness of movements, rigidity, gait disturbance and postural instability …

There is controversy regarding the definition and characteristics of mild cognitive impairment
in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to …

Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

Network analytical tools are increasingly being applied to brain imaging maps of resting
metabolic activity (PET) or blood oxygenation-dependent signals (functional MRI) to …

Although diagnosed by characteristic motor features, Parkinson's disease may be preceded,
and is frequently accompanied by, a wide range of cognitive and neuropsychiatric features …

Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic
importance. In addition, with the development of invasive therapies and novel disease …